CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

This study is testing a new CAR-T cell therapy targeting a protein called CD70, which is found on certain advanced solid tumors. The therapy uses a patient's own immune cells that are re-engineered to recognize and attack CD70-positive cancer cells. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced or metastatic solid tumor that tests positive for CD70 (confirmed by a tissue biopsy score of IHC 3+) - You have not responded to or cannot tolerate at least one standard second-line treatment (such as targeted therapy, PARP inhibitors, or anti-cancer surgery, chemotherapy, or radiation) - You have at least one measurable area of cancer on imaging - You have a good performance status (ECOG 0-1) **You may NOT be eligible if...** - Your tumor does not test positive for CD70 - You have serious active infections or immune system problems - You are pregnant or breastfeeding - You have brain metastases or significant heart or lung conditions Talk to your doctor to see if this trial is right for you.